| E. coli Clinical Isolates | Isolate ID | 4 | 40 | 44 | ||
| Sample Origin | Urine | Blood | Blood | |||
| Type of antibiotic | Antibiotic | MIC (µg/mL) | MIC (µg/mL) | MIC (µg/mL) | ||
| Resistance profile | Aminoglycosides | Amikacin | ≤2 (S) | ≤2 (S) | 32 (I) | |
| Gentamicin | ≤1 (S) | ≤1 (S) | ≥16 (R) | |||
| β-lactamases | Ampicillin | ≥32 (R) | ≥32 (R) | ≥32 (R) | ||
| β -lactam + β -lactamase inhibitor | Ampicillin/sulbactam | 8 (S) | 16 (I) | ≥32 (R) | ||
| Piperacillin/Tazobactam | ≤4 (S) | ≤4 (S) | ≥128 (R) | |||
| β -lactamases (cephalosporins) + β -lactamase resistant | 1st-generation | Cephalothin | 4 (S) | 16 (I) | ≥64 (R) | |
| 2nd-generation | Cefoxitin | ≤4 (S) | ≤4 (S) | ≤4 (S) | ||
| 3rd-generation | Cefotaxime | ≤1 (S) | ≤1 (S) | ≥64 (R) | ||
| Ceftazidime | ≤1 (S) | ≤1 (S) | ≥64 (R) | |||
| 4th-generation | Cefepime | ≤1 (S) | ≤1 (S) | ≥64 (R) | ||
| β-lactamases | Carbapenems | Imipenem | ≤1 (S) | ≤1 (S) | ≤1 (S) | |
| Meropenem | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) | |||
| ESBL | - | - | + | |||
| Quinolones | Ciprofloxacin | ≥4 (R) | ≤0.25 (S) | ≥4 (R) | ||
| Nalidixic acid | ≥32 (R) | ≤2 (S) | ≥32 (R) | |||
| Nitrofuran | Nitrofurantoin | ≤16 (S) | ≤16 (S) | ≤16 (S) | ||
| Co-trimoxazole | Trimethoprim/sulfamethoxazole | ≥320 (R) | ≤20 (S) | ≤20 (S) | ||